JERUSALEM , May 9, 2022
/PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:
BVXV), a biopharmaceutical company focused on developing,
manufacturing and commercializing innovative products for the
prevention and treatment of infectious diseases and other
illnesses, today announced that it will present at the
20th Biomed Israel Conference and Exhibition, to be held
May 10-12, 2022, in Tel Aviv, Israel.
The presentation, which will be delivered in-person by Dr.
Tamar Ben-Yedidia, BiondVax's
Chief Scientific Officer, on Thursday,
May 12th at 1:45pm, will focus on BiondVax's development
of innovative nanosized antibodies (NanoAbs) that exhibit
significant competitive advantages over existing therapies. The
NanoAbs are being developed in collaboration with the Max Planck
Institute for Multidisciplinary Sciences and University Medical
Center Göttingen (UMG), Germany,
to address diseases with large unmet medical needs and attractive
commercial opportunities such as asthma, psoriasis, psoriatic
arthritis, and macular degeneration.
Any attending investors that wish to meet with BiondVax
management at the conference are welcome to contact investor
relations.
Further information about the conference is available at
https://kenes-exhibitions.com/biomed/.
About BiondVax
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a
biopharmaceutical company focused on developing, manufacturing and
commercializing innovative products for the prevention and
treatment of infectious diseases and other illnesses. Since its
inception, the company has executed eight clinical trials including
a seven country, 12,400 participant Phase 3 trial of its vaccine
candidate and has built a state-of-the-art manufacturing facility
for biopharmaceutical products. With highly experienced
pharmaceutical industry leadership, BiondVax is aiming to develop a
pipeline of diversified and commercially viable products and
platforms beginning with an innovative nanosized antibody (NanoAb)
pipeline. For more information, please visit www.biondvax.com.
Contact Details
Company: Joshua E. Phillipson | +972 8 930 2529 |
j.phillipson@biondvax.com
Investor Relations: Kenny Green | +1
212 378 8040 | kgreen@edisongroup.com
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements regarding
participation in conferences, the timing of future clinical trials,
the therapeutic and commercial potential of NanoAbs and execution
of a definitive amendment agreement with EIB. These forward-looking
statements reflect management's current views with respect to
certain current and future events and are subject to various risks,
uncertainties and assumptions that could cause the results to
differ materially from those expected by the management of BiondVax
Pharmaceuticals Ltd. Risks and uncertainties include, but are not
limited to, the risk that the therapeutic and commercial potential
of NanoAbs will not be met; the risk of a delay in the preclinical
and clinical data for NanoAbs, if any; the risk that BiondVax and
EIB will not reach agreement with respect to the restructuring of
the loan from European Investment Bank; the risk that BiondVax may
not be able to secure additional capital on attractive terms, if at
all; the risk that the European Investment Bank may accelerate the
loans under its finance contract with BiondVax; risks relating to
the COVID-19 (coronavirus) pandemic; BiondVax's ability to acquire
rights to additional product opportunities; BiondVax's ability to
enter into collaborations on terms acceptable to BiondVax or at
all; timing of receipt of regulatory approval of BiondVax's
manufacturing facility in Jerusalem, if at all or when required; the
risk that the manufacturing facility will not be able to be used
for a wide variety of applications and other vaccine and treatment
technologies, and the risk that drug development involves a lengthy
and expensive process with uncertain outcomes. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
Annual Report on Form 20-F filed with the Securities and Exchange
Commission on March 28, 2022.
BiondVax undertakes no obligation to revise or update any
forward-looking statement for any reason.
View original
content:https://www.prnewswire.com/news-releases/biondvax-to-present-at-this-weeks-biomed-israel-conference-301542350.html
SOURCE BiondVax Pharmaceuticals Ltd.